We compared men and women treated before (baseline) and immediately after (post) GAP implementation. By using standard statistics, demographics, presentation variables, comorbidities, diagnostic test results, treatments (including evidence-based therapies and use of AMI discharge tools), and outcomes were analyzed in the 2 cohorts. We examined 30-day and 1-year mortality in the baseline sample compared with men and women in the post-GAP sample. To assess the potential independent benefit of GAP on mortality rates of men and women, separate multivariate logistic regression models for 30-day and 1-year mortality were developed for each sex, including use of the discharge document as an explanatory variable. Patients who died in the hospital were excluded from the patient population used to develop the postdischarge multivariate mortality models. Each hospital was also included as an independent variable into each model to account for practice variation between the facilities. Age, heart rate at admission, and troponin increases were analyzed as continuous variables, while all other variables were dichotomous. Candidate variables in each model included participation in the GAP program; use of the discharge tool; age; history of MI, congestive heart failure, cerebrovascular disease or stroke, hypertension, diabetes mellitus, and chronic obstructive pulmonary disorder; current smoking; percutaneous coronary intervention; and coronary artery bypass grafting. We also assessed in-hospital variables, including heart rate at admission, congestive heart failure, MI location, atrial fibrillation, hematocrit of less than 30%, reduced left ventricular ejection fraction, percutaneous coronary intervention, coronary artery bypass grafting, elevated creatine kinase level, hypotension, shock, stroke, renal failure, transfusion, and hemorrhage.